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ABSTRACT 
Aim Fracture risk is higher in older adults with Type 2 diabetes mellitus (T2DM). Oral 
glucose-lowering medications have different effects on bone metabolism. The purpose of this 
study is to appraise the evidence from literature and determine the effect of dipeptidyl 
peptidase-4 (DPP-4) inhibitor on the risk of developing bone fractures. 
Methods Using Boolean search terms, the search strategy combined synonyms of ‘fracture’ 
and ‘DPP-4 inhibitor’. Comprehensive electronic databases which include EMBASE, 
MEDLINE, the EMA and the WHO ICTRP databases were searched for randomised 
controlled trial (RCT) studies which compared a DPP-4 inhibitor with an active comparator 
or placebo amongst patients with T2DM. Meta-analysis was performed to compare DPP-4 
inhibitor with either an active comparator or a placebo. The outcome measure was the 
presence or absence of fracture. 
Results The search yielded 5,061 records relating to fractures and DPP-4 inhibitor, from 
which 51 eligible RCTs were selected for meta-analysis (N=36,402). Thirty-seven (37) 
studies compared DPP-4 inhibitor with placebo (n=23,974), while fourteen (14) studies 
(n=12,428) compared DPP-4 inhibitor with an active comparator. The mean age of patients 
was 57.5±5.4 years, the average glycated haemoglobin (HbA1c) was 8.2%, while the average 
BMI was 30±2 kg/m2. Overall, there was no significant association of fracture events with the 
use of DPP-4 inhibitor when compared with placebo (OR; 0.82, 95%CI 0.57-1.16, P = 0.9) or 
when DPP-4 inhibitor was compared against an active comparator (OR; 1.59, 95% CI 0.91-
2.80, P=0.9). 
Conclusion This study offers a larger, up-to-date review of the subject. The meta-analysis 
showed that there was no significant association between DPP-4 inhibitor use and the 
incidence of fractures. 
1. Introduction 
Patients with type 2 diabetes mellitus (T2DM) are associated with an increased risk of 
developing bone fractures1,2. This is related to a variety of factors, such as  recurrent falls3 
due to diabetes-related co-morbidities such as retinopathy, loss of balance, neuropathy and 
hypoglycaemic events1,4,5 as well as hyperglycaemia induced alterations in tissue/matrix 
composition leading to osteoporosis and bone fragility5. Glucose-lowering therapy (GLT) 
such as thiazolidinedione has been reported to reduce bone density6,7 and increase the risk of 
fractures.8,9  In addition, Insulin therapy is also associated with an increased fracture risk,10-12 
despite its neutral effect on bone density.13  
Experimental studies suggest that the incretin hormone glucagon like peptide-1 (GLP-1) and 
the gastric intestinal polypeptide (GIP) is capable of increasing bone density in animal 
models.14,15 GLP-1 has also been reported to induce osteoblast differentiation and inhibits 
osteoclast activity14,15. DPP-4 inhibitors is a widely used GLTs that inhibits the breakdown of 
these incretin hormones and therefore induce a rise in the level of these incretin hormones 
and may exert protective effects on the bone16.  Although bone mass density (BMD) has been 
shown to predict fracture incidence, BMD does not necessarily give a full picture of bone 
quality and strength.5 For example, a meta-analysis of over 65 studies showed that BMD was 
decreased in patients with Type 1 diabetes mellitus, but increased in those with T2DM.17 
However, despite this higher than normal BMD, patients with T2DM remains at an increased 
risk of fractures, by around 20% in both sexes.18 
A recent review and meta-analysis of RCT studies suggests that treatment with DPP-4 
inhibitors could be associated with a reduced risk of bone fractures.19 Monami et al., 
indicated that DPP-4 inhibitors, when compared with placebo or comparator treatments, were 
associated with fewer fracture events. The basis for this association may be explained by the 
protective effect of DPP-4 inhibitors on the bone. In a 2014 animal model study,20 the use of 
sitaglitpin (a DPP-4 inhibitor) in diabetic male rats increased trabecular bone volume, cortical 
bone volume and BMD. The loss of bone strength was attenuated, and bone biomarkers 
indicated a decrease in bone resorption. These findings are also supported by another study,21 
where high-fat diet-fed mice treated with sitagliptin showed an increase in vertebral BMD.  
At the time of previous systematic reviews, there was scarce research directly investigating 
the effect of DPP-4 inhibitors on fracture incidence. Fractures were often noted as adverse 
events, rather than primary endpoints. Other oral GLTs reduce glycated haemoglobin 
(HbA1c), however, they have not been shown to have the same protective effect on bone as 
DPP-4 inhibitors. Thus, factor independent of glycaemic control may influence fracture risk. 
Due to limitations of the previous review, which are later discussed in this study, it is 
necessary to undertake an updated systematic review and meta-analysis. This is especially 
considering that since the 2011 meta-analysis,19 a number of new robust RCTs investigating 
DPP-4 inhibitors have been published. The purpose of this study is to obtain an updated 
review and meta-analysis of the literature, to identify if DPP-4 inhibitors are associated with 
a decreased risk of bone fractures. Therefore, it is hypothesised that DPP-4 inhibitors will 
have a protective effect against fractures, as already demonstrated in an earlier review.19 
2. Methods 
2.1 Data sources and search strategy 
A series of searches were performed, investigating the association between fracture incidence 
and the use of DPP-4 inhibitors in patients with T2DM. Comprehensive electronic databases 
were searched. Using Boolean search terms, the search strategy combined synonyms of 
‘fracture’ and ‘DPP-4 inhibitor’. The data sources include EMBASE (1974-2015) and 
MEDLINE (1946-2015).  Reviews of approved drugs were identified manually on the 
European Medicines Agency (EMA) database. WHO International Clinical Trials Registry 
Platform (ICTRP), including clinicaltrials.gov, was searched to identify clinical trials. There 
was also manual searching of the supplementary data within the Monami et al., 2011 study.19 
2.2 Study selection and eligibility 
The preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2009 
checklist was used to structure the method of the review.  
The studies were assessed first by their titles, then by the abstract and followed by full text 
review. Titles and abstracts that were included mentioned synonyms for DPP-4 inhibitors, 
and the patient group with T2DM. Titles and abstract contradicting the search terms, by 
mentioning the wrong intervention, and conditions that were not T2DM were excluded. 
Within the clinicaltrials.gov searches, only the titles with the recruitment statuses, ‘not 
recruiting’ and ‘authorised’ were selected. Studies that were ‘not yet recruiting’, unfinished 
studies and studies without any data published were excluded. The relevant articles were 
assessed according to eligibility criteria.  
The aim of the search was to identify RCTs that compared the intervention with a comparator 
drug or placebo, amongst T2DM patients. Therefore, only RCTs were used as these are 
higher quality studies with better control and replicability. The intervention had to be either a 
DPP-4 inhibitor, and the outcome measure recorded was the number of fractures. The studies 
were manually searched for the term, ‘fracture’ to identify if fractures had occurred during 
the trial. If this was not present, then the study would be excluded. Non-English articles were 
not included. Only human studies were used, as these were the most relevant to application of 
results to patients with T2DM. There was no restriction on the publication date of articles, as 
all studies up until June, 2015 were included.  
2.3 Data abstraction 
The data of interest were the number of fracture events during the trials. A data extraction 
form was utilised to record different characteristics of each study; including the author, year 
of publication, clinical trial number, the duration of the trial (weeks), the intervention and 
comparator used, the number of participants in each group, sex (% of females), the mean age, 
the mean baseline HbA1c (%), mean baseline BMI (kg/m2), hypoglycaemic events (% of 
participants), and the number of fractures in both the intervention and the comparator groups.  
2.4 Data synthesis and analysis 
Eligible studies that were used in the meta-analysis were based on whether they included a 
DPP-4 inhibitor treatment, in addition to an active comparator or placebo treatment. Studies 
were also included that involved combination therapy within the intervention, active 
comparator or placebo arms.  
2.5 Meta-analysis 
Meta-analysis was conducted to assess and determine whether the use of DPP-4 inhibitor in 
the treatment of T2DM has a causal contribution to the development of bone fracture. Meta-
analysis was used to calculate the average measure of effect by assembling quantitative 
results from several RCT studies together. The number of fracture events reported in the 
exposed and unexposed (comparator) treatment groups of each primary study was extracted 
and used to calculate a new single measure of effect (pooled result or summary statistic). The 
pooled data from the studies were expressed as odds ratio, together with their precision (95% 
confidence interval). The results from all of the studies were summarized and displayed using 
forest plots. 
2.5.1 Assessing heterogeneity between studies 
Analysis was conducted to assess the similarity of results from each of the studies. The term 
heterogeneity was used to describe the degree to which the studies varied. The I2 statistical 
test was used to quantify the effect of heterogeneity between the results of the studies. I2 
value range from 0% to 100%, representing the percentage of total variation across the 
studies that is due to true heterogeneity rather than to chance. A value of 0% would indicate 
that there is no variability between studies that cannot be explained by chance, whereas, a 
value of 50% would indicate that 50% of the total variability in the meta-analysis is due to 
heterogeneity rather than to chance, and a value of 100% would indicate that all of the 
variation in the meta-analysis is due to heterogeneity rather than to chance.  I2 by itself was 
not used to explain the actual range of effects22 but was used together with the observed 
effects from the forest plots to get a sense of the absolute dispersion. 
2.5.2 Pooling meta-analysis data 
We considered the use of random effects model (where we assumed the true effect varied 
from study to study). We also considered the application of a fixed effects model (where we 
assumed that there was one true effect size shared by all the included RCT studies). The 
resulting I2 value determined which effect model was more favourable. If the I2 in the output 
is low (<40%), we would run the fixed effects model. The fixed-effects method was 
eventually used to pool the effect estimates of the studies together to generate the summary 
statistic odds ratio. The fixed effect method calculates a weighted average of the odds ratio 
from all of the different studies – the weight being proportional to the size of the study. 
Therefore the bigger the sample size of a study, the more influence it has on the pooled odds 
ratio. The fixed effect method assumes that all of the available studies are trying to estimate 
the same true value.23 
2.6 Bias assessment 
The JADAD scale was used to assess the method and appropriateness of randomisation, 
blinding and follow-up of participants in each study.24 A potential problem that can occur 
during the primary study search process is publication bias. This could occur when published 
studies that have found “interesting” (usually positive) results are more likely to be identified 
in during search and more likely to be published earlier than the “less interesting” (usually 
negative) ones. The extent of publication bias was assessed through the inspection of the 
magnitude of published effects in relation to the order of publication by year. In addition, 
funnel plots of the magnitude of the odds ratio against the study precision were used to assess 
the influence of publication bias.25,26 
3. Results 
The initial database searches identified 5,049 records relating to fractures and DPP-4 
inhibitors. In addition to this, 12 studies were manually identified from a previous meta-
analysis.19 From these, 51 studies met the criteria for inclusion in the meta-analysis as 
outlined in Figure 3.1. The patient characteristics of the eligible studies are summarised in 
Tables 3.1 and Table 3.2.   
3.1 Study characteristics 
The searches resulted in 51 RCTs with 36,402 participants. Thirty-seven (37) studies 
compared a DPP-4 inhibitor with a placebo, involving 23,974 patients. Fourteen (14) studies 
including 12,428 patients were used in the comparison of a DPP-4 inhibitor against an active 
comparator. The mean (standard deviation, SD) age of patients was 57.5 (5.4) years and 47% 
of the entire population was female. Participants had a mean (SD) body mass index (BMI) of 
30.2 (2.0) kg/m2. The average HbA1c was 8.2% and the percentage of patients who 
experienced a hypoglycaemic event was lower in the intervention compared to the 
comparator group (4.3% vs 5.3%, respectively).  
There were 39 multi-country trials, nine multisite trials, and two trials in the US. The 
durations of the studies ranged from 12 to 205 weeks, with an average of 47.8 weeks.  There 
were 29 RCTs with a duration < 52 weeks, and 22 studies were >52 weeks. The earliest dated 
study was in 2006,27 with the most recent study being published in 2014.28  
3.1.1 Intervention 
The DPP-4 inhibitors investigated in each RCT are as follows: 5 studies with alogliptin, 3 
with linagliptin, 12 studies with saxagliptin, 29 with sitagliptin and two studies with 
vildagliptin. Considering the placebo groups, a total of 28 studies (55%) had placebo in 
combination with another drug. Within the active comparator groups, five studies (35%) were 
combination therapies.29-33 Eight studies involved the use of metformin, and another eight 
studies involved the use of a sulfonylurea. Two studies included a thiazolidinedione,33,34 
while one study included a glucagon-like peptide-1 (GLP-1) receptor agonists31 and one 
study involved voglibose, an alpha-glucosidase inhibitor (AGI).35 Overall, there were 86 
cases of fracture in the intervention group, and 64 cases with the comparators. The most 
common types of fracture recorded include lower limb (12 cases), followed by ankle (10 
cases) and then rib (8 cases). 
3.1.2 Outcomes 
All studies had a primary outcome measure of HbA1c change from baseline. This is with the 
exception of Alba et al.,36 who measured changes in α-cell and β-cell function; insulin 
secretion rate in the clinical trial study NCT00374907;37 the percentage of individuals 
experiencing a primary major cardiac event (MACE) in NCT00968708;38 and the proportion 
of patients under a HbA1c of 7.0% without any sings of severe hypoglycaemia, as measured 
in NCT01006603.39 The secondary outcomes were varied, but mostly included efficacy 
assessments such as change in glucose, insulin, proinsulin, fasting plasma glucose (FPG), 2-
hour post-meal glucose (PMG), body weight and fasting lipids. Two studies included safety 
assessments such as blood pressure and cases of secondary MACE.38,40 
3.1.3 RCT exclusion and inclusion criteria 
Two authors participated in the literature search, while agreement on criteria for inclusion of 
RCTs was reached by consensus between 3 authors. The studies had mostly similar inclusion 
criteria, with no restrictions on the gender of the patient. Studies were restricted to patients 
with T2DM with inadequate glycaemic control either with diet and exercise alone. The mean 
range of requirements, inclusively were an HbA1c level from 7 to 10%; a BMI between 22 to 
43kg/m2; and age 22 to 78 years. Eleven studies required the patients to be unlikely to 
conceive, or to use contraception. Two studies set limitations for blood pressure (BP),41,42 
only including participants with a BP up to 170/105mmHg. On average, three studies 
required patients to have had diabetes duration for a minimum of 2 years.36,43,44 Four studies 
included patients with renal impairment.45-48 One study,38 used patients with acute coronary 
syndrome between 15 and 90 days prior to the study. Two studies only included patients that 
would have the ability to use home blood glucose monitoring,29,49 and one study included the 
patients able to use an injection device.31 
Exclusion criteria differed across the study, but the most commonly encountered criteria 
were; a history of CV event; females who are pregnant or breastfeeding; patients that refused 
the use of contraception; the presence of hepatic and renal disease; secondary forms of 
diabetes; Type 1 diabetes mellitus; a history of diabetic ketoacidosis; symptoms of poorly 
controlled diabetes; recent gastrointestinal surgery; the prior use of a weight loss drug 
treatment; the use of any other hyperglycaemic agents; alcohol and substance use; 
hypersensitivity to any of the treatments; and uncontrolled hypertension. 
3.2 Meta-analysis 
3.2.1 DPP-4 inhibitor and fracture incidence 
Statistical analysis was carried out in order to investigate the association of fractures with the 
use of DPP-4 inhibitors. The primary outcome was the number of fracture events. From 
these, the odds ratio (OR) was calculated. Two subgroup analyses were performed, 
comparing the incidence of fractures with DPP-4 inhibitors; and active comparators or a 
placebo. Overall there was no significant association of fracture events with the use of DPP-4 
inhibitors. 
3.2.2 DPP-4 inhibitor vs placebo 
A subgroup analysis comparing DPP-4 inhibitors to placebo is displayed by the forest plot in 
Figure 3.2. The I2 value obtained was equal to 0.0%, indicating no presence of heterogeneity. 
Results from the fixed effect model analysis gave a non-significant P value of 0.9. The OR 
was 0.82 with a 95% CI of 0.57-1.16. 
3.2.3 DPP-4 inhibitor vs active comparator 
A subgroup analysis on DPP-4 inhibitors compared with an active comparator is displayed by 
the forest plot in Figure 3.3. The I2 value was equal to 0.0%, indicating homogeneity. The OR 
of 1.59 with a 95%CI of 0.91-2.80 (P value, 0.9) was obtained from the fixed effect model. 
3.3 Bias assessment 
3.3.1 Quality assessment 
The JADAD scale was used to assess the quality of each study. Thirteen (13) studies obtained 
a score of 5, thirty one (31) studies obtained a score of 4, while seven (7) studies obtained a 
score of 3, with no study obtaining a score below 3. The average score was 4, therefore the 
overall quality of RCTs was good. 
3.3.2 Randomisation and blinding 
All studies were randomised, with 9 studies being randomised by computer generated 
allocation. 36 studies did not mention the method used for randomisation. 7 studies were 
stratified according to certain factors. Forty three of the studies were double-blind with a 
matching placebo. Seven studies did not use a placebo, and one study was open label.31  
3.3.3 Publication bias 
The effect of publication bias was reduced by ensuring that the systematic review of 
published literature was as thorough as possible. Additional hand searching of references 
quoted by each paper was done to make sure all relevant literature was found. Unpublished 
data were also obtained and included, which may reduce publication bias, although this may 
also decrease validity as unpublished work has not been peer reviewed. The funnel plots 
presented in Supplementary Figures 1 and 2 show the funnels are approximately symmetrical, 
indicating the absence of publication bias. 
4. Discussion 
This systematic review and meta-analysis studied the effect of DPP-4 inhibitors on fracture 
incidence in T2DM. The meta-analysis of 51 RCTs showed that there was no significant 
association between DPP-4 inhibitor use and the occurrence of fractures when DPP-4 
inhibitor is compared with placebo or active comparator. 
From the quality assessments, it can be concluded that the RCT studies were well-designed, 
giving rise to evidence of a good strength. The forest plots and I2 values of 0.0% in both 
meta-analyses indicated that there was no statistical heterogeneity. This means that any 
variability across the studies could be attributable to chance, not to the heterogeneity of the 
studies themselves.50 This consistency amongst studies should provide a confidence in 
applying these results.51 Therefore, results from this meta-analysis can be considered to have 
a good level of internal validity. In addition, the large sample size and multinational 
representation reflects this study’s external validity.  
In the context of the research surrounding the role of incretin hormones in bone metabolism, 
this study demonstrates no significant reduction of fracture incidence with the use of DPP-4 
inhibitors. This is in contrast to Monami et al.,19 who displayed that there was a statistically 
significant association between DPP-4 inhibitor use and reduced occurrence of fracture. From 
Monami et al study, 17 of the 20 trials comparing DPP-4 inhibitors with placebo were used in 
this meta-analysis. Three trials were not included, since these did not mention that a fracture 
event occurred during the study.52-54 There was also no mention that authors of the original 
studies were contacted for this information. The limitations associated with the review by 
Monami et al emphasised the necessity of an updated meta-analysis comprising of a greater 
number of patient data. Furthermore, this meta-analysis included 22 trials with study duration 
of 52 weeks and above, whereas the previous review included only 7 trials with ≥52 weeks.19 
Another meta-analysis of RCT studies by Su et al55 examined the risk of bone fractures 
associated with GLP-1 receptor agonists (liraglutide and exenatide) when compared with 
placebo or active comparator treatment. Incident fracture data from 11,206 patients was 
pooled across 16 RCTs and the results showed treatment with liraglutide was associated with 
a significant reduction in the risk of bone fracture (MH-OR: 0.38, 95% CI: 0.17–0.87), while 
treatment with exenatide was associated with an increased risk of bone fractures (MH-OR: 
2.09, 95% CI: 1.03–4.21).  
The contrasting results that have emerged from these incretin-based therapy review studies 
show the need for further investigations into the role of incretin hormones in bone 
metabolism across various populations. The reason for this disparity between results from 
previous reviews and this current review study cannot be explained from our data. However, 
we assume that other underlying factors such as lifestyle changes might play a significant 
role. The disparity in the results obtained from previous reviews of RCTs implies that that a 
definitive conclusion cannot be made on the effect of DPP-4 inhibitor on bone fractures in the 
long-term.  
The SAVOR-TIMI 53 study by Scirca et al.,56 was conducted across 16,492 T2DM patients 
for a median of 2.1 years. This large, multisite, double-blind RCT investigated cardiovascular 
outcomes in T2D patients, comparing the effects of saxagliptin with placebo. In keeping with 
this meta-analysis, it was found that there was no significant difference in the number of 
patients experiencing a fracture, between the saxagliptin and placebo group (P = 1.0). In 
addition, a large-scale retrospective cohort study by Driessen et al.,57 directly investigated the 
effect of DPP-4 inhibitor use on fracture risk. Information from the Clinical Practice 
Research Datalink (CPRD) database on 216,816 patients was examined. The study 
demonstrated no significant difference in the hazard risk of fractures, between DPP-4 
inhibitor users and matched control patients (adjusted hazard ratio 0.89; 95% CI of 0.71-
1.13).  
The studies included in our review are not without their limitations. For example, RCTs had 
an average duration or follow-up of 37.5 weeks. This may be too short of a follow-up time to 
observe fracture events.  In addition to this, fracture was not reported as a primary end-point 
in any of the studies, but only as an adverse event.  
As in the previous review,19 combination therapy was also included within the intervention, 
active comparator and placebo arms. As a result, the inclusion of these combination therapies 
may have exerted an effect on the outcome (the number of fractures). In future, a meta-
regression could be performed, in order to identify the significance of this effect. 
Nonetheless, the presence of combination therapies in many patients accurately reflects the 
reality that single drug therapy is often insufficient to control glycaemic levels. 
Another limitation of this review was the unavailability of some data, especially within 
unpublished, yet disclosed trials from the clinicaltrials.gov website.  If a published article 
referring to the same clinical trial identifier number could be identified, missing data were 
obtained from that source. In the case that there was no published article for a clinical trial, or 
no additional information within the published article, data were marked as ‘not reported’ 
(NR). It is acknowledged that this missing data may have given an incomplete picture of 
patient characteristics. However, the data that were missing did not relate to the outcome 
measure of this review.  
The use of RCTs provides a high level of internal validity, improving the strength of 
recommendation for the practice of evidence-based medicine. Still, RCTs may not have a 
high level of external validity. This is since they may not accurately reflect a real-world 
environment where factors are not so tightly controlled. However, these rigorous methods 
allow the conclusion to be made, that the difference in the outcome being measured, is in fact 
due to a change in the independent variable. This systematic review has demonstrated the 
absence of a significant association between DPP-4 inhibitor and fracture incidence. 
While DPP-4 inhibitors have not been shown to significantly protect against fracture, this 
research is still valuable in informing the choices of healthcare providers in prescribing 
treatments from this class of drugs. For the users of this treatment, it is good news that DPP-4 
inhibitors are not generally associated with fracture incidence, in contrast to 
thiazolidinedione, which are known to be associated with increased fracture risk, or with 
exenatide, which was recently shown to be associated with increased risk of bone fracture.55 
The results drawn from RCTs in the field are varied, meaning that a definitive conclusion 
cannot be made on the role of DPP-4 inhibitors in protecting against bone fractures. The 
results of this review imply that future research should include studies of a longer duration. In 
addition, more studies are required to directly investigate the number of fractures with the use 
of DPP-4 inhibitors, as a primary endpoint, rather than an adverse event.  
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Table 3.1: Patient characteristics for RCT studies involving DPP-4 inhibitor and placebo 
Author, Year 
Clinical trial 
No. population 
F, 
% Age, yrs 
HbA1c, 
% BMI Wks Intervention n 
No. of 
fractures Comparator n 
No. of 
fractures 
Hollander, 
2011 
NCT00295633 Multisite 51 54 (0.9) 8.3 (0.1) 30 (0.3) 76 Sitagliptin 
(2.5mg, 5mg) 
381 5 Placebo/TZD 184 1 
Yang, 2011 NCT00661362 Multisite in 
China, India, 
South Korea 
52 54 (0.4) 7.9 (0) 26.2 (0.1) 24 Saxagliptin 
(5mg) 
283 3 Placebo/Metformin 287 0 
Scherbaum, 
2008 
NCT00101712 Multisite in 
Europe 
41 63 (0.4) 6.8 (0.1) 30.2 (0.3) 52 Vildagliptin 
(50mg) 
156 0 Placebo 150 1 cervical 
Fonseca, 2007 NCT00099931 Multi-
country 
49 59 (0.5) 8.4 (1.1) 33.1 (5.6) 24 Vildagliptin 
(50mg) BID 
144 0 Placebo/Insulin 152 1 
NCT00286468 NCT00286468 Multi-
country 
48 57 (0.4) 8.1 (0) 30.1 (1.1) 26 Alogliptin 
(12.5mg, 25mg) 
401 1 spinal 
compression 
Placebo/Glyburide 99 0 
Dobs, 2013 NCT00350779 Multi-
country 
42 55 (0.3) 8.8 (1) 30.3 (6) 54 Sitagliptin 
(100mg) 
170 0 Placebo/Rosiglitazo
ne/ 
Metformin 
92 1 lower limb 
NCT01076075 NCT01076075 NR 54 55 (0.7) 8.4 (0.8) NR  54 Sitagliptin 
(100mg) 
210 0 Placebo/Pioglitazon
e 
212 1 skull 
Barnett, 2013 NCT01084005 Multi-
country 
33 75 (0) 7.8 (0.1) 29.7 (0.1) 24 Linagliptin 
(5mg) 
162 1 lower 
limb                                              
1 vertebra 
Placebo 79 0 
NCT00316082 NCT00316082 Multi-
country 
54 55 (10) 7.9 (0.1) NR  24 Saxagliptin 
(2.5mg, 5mg) 
291 1 femoral 
neck                                    
1 spinal  
Placebo 74 0 
Jadzinsky, 2009 NCT00327015 Multi-
country 
51 52 (11) 9.5 (0.1) 30.2 (4.8) 24 Saxagliptin 
(5mg, 10mg) 
643 1 upper 
limb 
1 wrist 
Placebo/Metformin 328 0 
Chacra, 2009 NCT00313313 Multi-
country 
55 55 (10) 8.4 (0.1) 29 (4.6) 24 Saxagliptin 
(2.5mg, 5mg) 
501 1 lower 
limb 
Placebo/Glyburide 267 0 
NCT00305604 NCT00305604 US 35 72 (6) 7.8 (0.7) NR  24 Sitagliptin 
(50mg/ 
100mg) 
102 0 Placebo 104 1 lumbar 
vertebra,                        
1 upper limb 
Fonseca, 2013 NCT00885352 Multi-
country 
38 56 (9) 8.7 (1) 30 (5.2) 26 Sitagliptin 
(100mg) 
157 0 Placebo 156 1 patella 
NCT00121667 NCT00121667 Multi-
country 
49 55 (10) 8.1 (0.1) 31.4 (4.9) 24 Saxagliptin 
(2.5mg, 5mg, 
10mg) 
564 4 Placebo/Metformin                           
/Pioglitazone 
179 0 
Goldstein, 2007 NCT00103857 Multi-
country 
50 53 (9.9) 9 (1.2) 32.1 (6.6) 24 Sitagliptin 
(50mg BID, 
551 1 femur Placebo/Metformin 176 0 
Author, Year 
Clinical trial 
No. population 
F, 
% Age, yrs 
HbA1c, 
% BMI Wks Intervention n 
No. of 
fractures Comparator n 
No. of 
fractures 
100mg QD) 
NCT00087516 NCT00087516 Multi-
country 
48 54 (9.9) 8 (0.9) NR  24 Sitagliptin                                    
(100mg, 
200mg) 
488 0 Placebo 253 1 ankle 
NCT00086515 NCT00086515 Multi-
country 
43 55 (10) 8 (0.8) NR  104 Sitagliptin 
(100mg) 
464 0 Placebo/Glipizide 237 1 traumatic 
NCT01215097 NCT01215097 Multisite in 
China, 
Malaysia, 
Philippines 
50 56 (10) 8 (0.8) 25.6 (4) 24 Linagliptin 
(5mg) 
205 1 
comminuted 
Placebo 100 0 
NCT00984867 NCT00984867 Multi-
country 
45 55 (10) 7.9 (0.8) NR  24 Sitagliptin 223 0 Placebo/Sitagliptin/ 
Metformin 
224 1 upper limb 
NCT00968708 NCT00968708 Multi-
country 
32 61 (9.9) NR  29.5 (5.6) 205 Alogliptin 
(6.25mg/ 
12.5mg/ 25mg) 
2701 13 Placebo 2679 21 
NCT00757588 NCT00757588 Multi-
country 
59 57 (9.4) NR  NR  24 Saxagliptin 
(5mg) 
304 1 ankle Placebo/Insulin 151 0 
NCT00734474 NCT00734474 Multi-
country 
54 54 (9.9) 8.1 (1.1) 31.3 (4.4) 104 Sitagliptin 
(100mg) 
492 2 Placebo/Dutaglutide
/Metformin 
710 4 
NCT00800683 NCT00800683 Multi-
country 
40 64 (10) 8.2 (1) 32 (5.8) 52 Linagliptin 
(5mg) 
68 1 femur 
1 humerus 
Placebo 65 0 
Henry, 2014 NCT00722371 NR 44 52 (1.1) 8.8 (1.1) 30.9 (5.4) 54 Sitagliptin 
(100mg) 
922 2 foot 
1 upper 
limb 
Placebo/ 
Pioglitazone 
693 1 foot 
Alba, 2013 NCT00511108 Multi-
country 
45 54 (7.9) 7.9 (1) 30.9 (4.8) 21 Sitagliptin 
(100mg) 
104 1 tibia Placebo/Pioglitazon
e 
107 0 
Yoon, 2011 NCT00397631 Multi-
country 
46 51 (11) 9.5 (1.2) 29.7 (5.2) 24 Sitagliptin 
(100mg) 
261 1 humerus Placebo/ 
Pioglitazone 
259 0 
Vilsboll, 2010 NCT00395343 Multi-
country 
49 58 (9.2) 8.7 (0.9) 31 (5) 24 Sitagliptin 
(100mg) 
322 1 pelvic Placebo/Insulin/                                                
Metformin 
319 0 
NCT00374907 NCT00374907 US 61 57 (2.1) NR  32.8 (0.7) 116 Saxgliptin 
(5mg) 
20 1 ankle Placebo/Metformin 16 0 
NCT00372060 NCT00372060 Multisite in 
Japan 
35 58 (9.5) 7.7 (0.8) NR  52 Sitagliptin 
(50mg-100mg) 
133 1 patella 
1 rib 
Placebo/Sitagliptin            
Pioglitazone 
68 1 lower limb 
NCT00337610 NCT00337610 Multi-
country 
54 55 (9.5) 9.2 (0.8) NR  30 Sitagliptin 
(100mg) 
96 0 Placebo/Metformin 94 1 upper limb 
DeFronzo,2012 NCT00328627 Multi-
country 
55 54 (9.5) 8.5 (0.7) 31.2 (5.1) 26 Alogliptin 
(12.5mg, 25mg) 
1037 0 Placebo/Pioglitazon
e 
518 1 ankle 
NCT00838903 NCT00838903 Multi-
country 
52 55 (10) NR  NR  156 Sitagliptin 
(100mg) 
302 1 femur 
1 spinal 
Placebo/Metformin 101 0 
Author, Year 
Clinical trial 
No. population 
F, 
% Age, yrs 
HbA1c, 
% BMI Wks Intervention n 
No. of 
fractures Comparator n 
No. of 
fractures 
Study 057 NR Multisite 59 57 (NR) 8.7 (0.9) 32.3 (NR) 52 Saxagliptin 
(5mg) 
304 2 foot 
1 ankle 
Placebo/Insulin 
 
151 1 hand,  
1 humerus,                  
1 lower limb 
Rosenstock, 
2006 
NCT00086502 Multi-
country 
45 56 (11) 8 (0.8) 31.5 (5.1) 24 Saxagliptin 
(100mg) 
175 0 Placebo/Pioglitazon
e 
178 1 lower limb 
Study 
D1680L00006 
NCT01128153 Multi-
country 
40 57 (11) 8.3 (0.8) 29.2 (5.1) 24 Saxagliptin 
(5mg) 
129 0 Placebo/Metformin/               
Sulfonylurea 
128 1 rib 
NCT01098539 NCT01098539 Multi-
country 
46 63 (8.7) NR  NR  52 Sitagliptin 
(25mg-100mg) 
246 0 Placebo/Albiglutide 249 1 radius, 
1 sternal 
Arjona Ferreira, 
2013a 
NCT00509262 Multi-
country 
40 64 (10) 7.8 (0.7) 26.8 (4.8) 54 Sitagliptin 
(25mg/ 
50mg) 
211 1 patella Placebo/Glipizide 212 1 femur 
Abbreviation: F (female); Wks (duration in weeks); n (sample size); BMI (body mass index in Kg/m2); HbA1c (glycated haemoglobin); TZD (thiazolidinedione); NR (not reported); 
Mean (standard deviation) reported for age, HbA1c and BMI. 
The patients had a mean age of 57 years, ranging from 50.9 to 74.9 years. There were 48 cases of fracture amongst 10,051 patients in the placebo group, and 55 fractures amongst 13,923 patients taking a 
DPP-4 inhibitor 
 
  
Table 3.2: Patient characteristics for RCT studies involving DPP-4 inhibitor and active comparator 
Author, Year Clinical trial 
No. 
Population F, 
% 
Age, yrs Hba1c,
% 
BMI Wks Intervention n No. of 
fractures 
Comparator n No. of 
fractures 
Iwamoto, 2010 NR Japan 34 61 (10) 7.8 (0.9) 24.7 (3.5) 12 Sitagliptin 
(50mg) 
163 0 Voglibose 
(0.2mg) TID 
156 1 foot 
NCT00707993 NCT00707993 Multi-
country 
55 70 (4.2) NR  29.8 (4.4) 52 Alogliptin 
(25mg) 
222 1 multiple 
1 upper limb 
Glipizide (5mg) 219 1 stress 
NCT00856284 NCT00856284 Multi-
country 
50 55 (9.7) 7.6 (0.6) 31.2 (5.4) 104 Alogliptin 
(12.5mg, 25mg) 
1765 3 ankle 
1 femur 
1 tibia 
1 comminuted 
Glipizide 
(5mg-20mg)/ 
Metformin 
(1500mg-3300mg) 
874 1 ankle                                             
1 facial bone                                         
1 lower limb 
NCT01006603 NCT01006603 Multi-
country 
38 73 (5.6) NR  NR  52 Saxagliptin 
(5mg) 
360 2 lumbar 
vertebra                   
1 femur 
1 hand 
Glimepiride 
(1mg-6mg) 
360 1 ankle 
Schernthaner, 
2013 
NCT01137812 Multi-
country 
44 57 (9.5) 8.1 (0.9) 31.6 (6.9) 52 Sitagliptin 
(100mg) 
378 1 lower limb Canagliflozin 
(300mg)/Metformin/                
Sulfonylurea 
377 1 hand 
1 hip 
Nauck, 2007 NCT00094770 Multi-
country 
41 57 (9.6) 7.7 (0.9) 31.3 (5.1) 52 Sitagliptin 
(100mg) 
588 1 lower limb 
1 radius              
 1 tibia 
Glipizide 
(5mg-20mg) 
584 1 ankle 
1 lower limb                                                 
1 radius 
Charbonnel, 
2013 
NCT01296412 Multi-
country 
45 57 (10) 8.2 (1) 32.7 (6) 26 Sitagliptin 
(100mg) 
326 1 rib                                                  
1 spinal 
compression                          
1 sternal 
Liraglutide
(0.6mg-1.8mg)/                     
Metformin 
(>1500mg) 
327 0 
Arechavaleta, 
2011 
NCT00701090 Multi-
country 
46 56 (9.9) 7.5 (0.7) 30 (4.5) 30 Sitagliptin 
(100mg) 
516 1 humerus 
1 patella 
Glimepiride 
(1mg-6mg)/                                
Metformin 
(>1500mg) 
519 1 clavicle 
Wainstein, 2012 NCT00532935 Multi-
country 
46 52 (11) 8.9 (1.3) 29.8 (5.8) 35 Sitagliptin 
(50mg) BID 
261 1 femur Pioglitazone                          
(30mg-45mg) 
256 0 
Arjona Ferreira, 
2013b 
NCT00509236 Multisite 40 60 (9.5) 7.9 (0.7) 26.8 (5) 54 Sitagliptin 
(25mg) 
64 1 hip 
1 pelvic 
Glipizide                                    
(2.5mg-20mg) 
65 0 
Aschner, 2010 NCT00449930 Multi-
country 
54 56 (11) 7.3 (0.7) 30.8 (4.8) 24 Sitagliptin 
(100mg) 
528 1 tibia Metformin                       
(500mg-1000mg) BID 
522 0 
Goke, 2013 NCT00575588 Multi-
country 
48 58 (10) 7.5 (0.1) 31.4 104 Saxagliptin 
(5mg) 
428 1 femoral neck                        
1 lumbar     
vertebra                              
1 patella                                       
1 upper limb 
Glipizide (5-20mg)/                             
Metformin 
430 1 femur 
1 humerus 
Author, Year Clinical trial 
No. 
Population F, 
% 
Age, yrs Hba1c,
% 
BMI Wks Intervention n No. of 
fractures 
Comparator n No. of 
fractures 
Study P049 NR Multisite 54 56  7.2  NR  24 Sitagliptin 
(100mg) 
455 1 tibia Metformin (2000mg) 439 0 
NCT00482729 NCT00482729 Multisite in 
US, Puerto 
Rico 
43 50 (11) 9.9 (1.8) NR  44 Sitagliptin 
(50mg) BID 
625 1 rib Metformin                                      
(500mg-1000mg) BID 
621 1 rib, 1 skull 
Abbreviation: F (female); Wks (duration in weeks); n (sample size); BMI (body mass index in Kg/m2); HbA1c (glycated haemoglobin); TZD (thiazolidinedione); NR (not reported); 
Mean (standard deviation) reported for age, HbA1c and BMI. 
The patients had a mean age of 58 years, ranging from 49.7 to 72.6 years. There were 16 cases of fracture amongst 5,749 patients in the active comparator, and 31 fractures with 6,679 patients in the 
intervention group. 
 
